Intellia Dismisses Four Counterclaims in BlueAllele Patent Suit
Intellia Therapeutics Inc. has dismissed four counterclaims, including one regarding patent inventorship and claims of tortious interference and unfair trade practices, in BlueAllele Corp.'s gene-editing patent infringement lawsuit. This follows a previous dismissal of Intellia's unjust enrichment counterclaim. The dismissals were granted with prejudice by Judge John F. Murphy in the US District Court for the District of Delaware.
Intellia’s CRISPR Submission Is a Regulatory Stress Test the FDA Has Never Faced Before
Intellia Therapeutics' submission of its CRISPR-based gene editing therapy, nex-z, presents an unprecedented regulatory challenge for the FDA. Unlike previous gene therapies, nex-z involves a permanent, single-dose genomic edit, raising complex questions about long-term monitoring, off-target risks, and who bears the cost and responsibility for decades of follow-up. The article argues that the FDA's current guidance is not equipped for the unique characteristics of in vivo CRISPR and must evolve to establish a new regulatory architecture for this transformative technology.
Does Intellia Therapeutics (NTLA) Cash Runway Truly Offset Dilution Concerns From Its Recent Equity Raise?
Intellia Therapeutics reported a narrower net loss in Q1 2026, but concerns persist regarding dilution from its recent $180 million equity offering. The company highlights a multi-year cash runway, shifting focus to the execution of its gene-editing pipeline and clinical milestones, particularly the regulatory path for lonvo z. Investors are watching to see if future funding needs can be managed without further significant dilution.
Does Intellia Therapeutics (NTLA) Cash Runway Truly Offset Dilution Concerns From Its Recent Equity Raise?
Intellia Therapeutics reported an improved net loss in Q1 2026 but faces ongoing concerns about dilution following an April equity offering. Despite management's assertion of a multi-year cash runway, investors are closely watching the progress of its gene-editing pipeline, particularly the regulatory path of lonvo-z, to see if future funding needs can be controlled. The article highlights that while the equity raise provides capital, the risk of further dilution remains if cash burn continues at current levels.
Intellia Therapeutics stock (US45826J1051): gene-editing pipeline update keeps investors focused on
Intellia Therapeutics continues to attract investor attention as it advances its CRISPR-based gene-editing pipeline. The company focuses on both in vivo and ex vivo approaches to develop one-time treatments for serious diseases, with its financial performance currently driven by collaboration and license agreements rather than product revenue. Investors are closely monitoring upcoming clinical trial readouts, regulatory milestones, and partnership developments to assess the potential of its therapies and navigate the competitive gene-editing landscape.
A Look At Intellia Therapeutics (NTLA) Valuation After Recent Gene Editing Trial And BLA Progress
Intellia Therapeutics (NTLA) has shown improving momentum after positive Phase 3 HAELO results for lonvo-z, the start of a rolling biologics license application, and resumed ATTR amyloidosis trials. While the stock is significantly down from its three and five-year highs, recent gains suggest a re-evaluation of its gene editing pipeline. The article explores whether the current stock price implies a genuine discount given its clinical progress and financial discipline, or if future growth is already priced in, highlighting a narrative suggesting it's 51% undervalued despite a high Price/Sales ratio compared to peers.
A Look At Intellia Therapeutics (NTLA) Valuation After Recent Gene Editing Trial And BLA Progress
Intellia Therapeutics (NTLA) is drawing attention after positive Phase 3 results for lonvo-z, progress on its biologics license application, and resumed ATTR amyloidosis trials. While recent short-term share price performance has been mixed, longer-term returns suggest improving momentum. The article explores whether the stock's current valuation, well below previous highs, represents a genuine discount or if future growth is already accounted for, noting that it appears undervalued based on one narrative but has a rich sales multiple compared to peers.
Earnings Update: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Intellia Therapeutics (NASDAQ: NTLA) reported first-quarter results that surpassed analyst expectations, with revenues of US$15m beating forecasts by 9.0% and statutory losses being 9.0% smaller than anticipated. Following these results, analysts maintained their revenue forecasts for 2026 at US$60.4m but moderately upgraded their loss per share forecasts to US$3.25, suggesting an improvement in sentiment. The average price target remained steady at US$26.65, though there is a wide spread in analyst valuations, indicating divergent views on the company's future performance.
Wedbush Remains a Hold on Intellia Therapeutics (NTLA)
Wedbush maintained a Hold rating on Intellia Therapeutics (NTLA) with a $12.00 price target. The company reported a quarterly revenue of $23.02 million and a GAAP net loss of $95.79 million. Insider sentiment is negative, with an increase in share sales by corporate insiders over the past quarter.
Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline
Intellia Therapeutics (NTLA) reported a Q1 2026 net loss of US$96.2 million on US$15.0 million revenue, similar to the previous quarter, raising questions about its path to profitability. Despite analysts projecting 64.4% annual earnings growth and profitability within three years, the company's premium P/S multiple of 29.6x and ongoing losses concern cautious investors. While a DCF fair value is significantly higher, this relies on future revenue growth and profitability, with continued dilution being a risk.
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
Intellia Therapeutics (NTLA) reported a narrower Q1 2026 loss per share of 81 cents, beating analyst estimates, although revenues of $15 million missed the mark. The company's stock has surged over 60% year-to-date. Intellia provided updates on its pipeline, including the lifting of FDA clinical holds for its nex-z program in ATTR amyloidosis and positive phase III results for lonvo-z in hereditary angioedema, with a BLA submission for lonvo-z expected in H2 2026.
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics announced its first quarter 2026 financial results and provided business updates. Key highlights include positive Phase 3 HAELO data for lonvo-z in HAE, the initiation of a rolling BLA submission for lonvo-z with an anticipated U.S. launch in early 2027, and the resumption of patient screening for two Phase 3 trials of nex-z in ATTR. The company also reported a cash position of $517.2 million as of March 31, 2026, and expects existing funds, including proceeds from a recent offering, to cover operations into 2028.
[10-Q] Intellia Therapeutics, Inc. Quarterly Earnings Report
Intellia Therapeutics, Inc. (NTLA) filed its Quarterly Earnings Report (10-Q) for the period ended March 31, 2026. The company reported a net loss of $96.2 million for the first quarter of 2026, an improvement from $114.3 million in the prior year primarily due to decreased research and development expenses. Intellia also highlighted positive topline data from its Phase 3 HAELO clinical trial for lonvo-z in hereditary angioedema (HAE) and the lifting of clinical holds on its Phase 3 trials for nex-z in transthyretin (ATTR) amyloidosis, with plans for a commercial launch of lonvo-z in the first half of 2027.
Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest
Intellia Therapeutics (NTLA) is a "battleground stock" with 38.31% short interest, reflecting significant market skepticism despite recent positive clinical developments. The FDA's decision to lift clinical holds on the MAGNITUDE and MAGNITUDE-2 trials for nexiguran ziclumeran (nex-z) has de-risked a key part of its pipeline, potentially setting the stage for a short squeeze. While safety concerns and cash burn are bear arguments, strong institutional backing and promising data for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) present a high-risk, high-reward opportunity.
Intellia Therapeutics, Inc. (NTLA) reports Q1 loss, misses revenue estimates
Intellia Therapeutics, Inc. (NTLA) announced a Q1 loss of 99 cents per share, which was wider than the Zacks Consensus Estimate of a 91 cents loss per share. The company also reported revenue of $36.33 million, falling short of the Zacks Consensus Estimate of $50 million and showing a year-over-year decrease of 23.32%.
Intellia Therapeutics, Inc. Q1 2026: Revenue $15M, EPS $(0.81) — 10-Q Summary
Intellia Therapeutics, Inc. (NTLA) reported its Q1 2026 results, with revenue of $15 million and a net loss of $96.2 million, resulting in a diluted EPS of $(0.81). The company saw reduced revenue compared to Q1 2025 but an improved net loss. Key business highlights include positive Phase 3 results for lonvo-z, initiation of a rolling BLA for its U.S. launch, lifted FDA clinical holds for nex-z trials, and strategic reductions in R&D spending to focus on lead programs and commercial readiness.
One-time CRISPR shot cuts HAE attacks 87% in Intellia trial
Intellia Therapeutics reported positive Phase 3 HAELO trial results for lonvo-z, a one-time CRISPR gene editing treatment for hereditary angioedema (HAE), showing an 87% reduction in attack rates against placebo. The company is initiating a rolling Biologics License Application (BLA) submission with the FDA, aiming for a potential U.S. launch in the first half of 2027. Additionally, the FDA lifted clinical holds on its nex-z ATTR trials, and Intellia's financial position, bolstered by a recent equity offering, is expected to fund operations at least into 2028.
Intellia Therapeutics (NTLA) posts Q1 loss but advances lonvo-z and nex-z
Intellia Therapeutics reported a Q1 2026 net loss of $96.2 million but announced significant progress in its gene-editing programs. The company achieved positive Phase 3 results for lonvo-z in hereditary angioedema (HAE) and initiated a rolling BLA submission, targeting a U.S. launch in H1 2027. Additionally, the FDA lifted clinical holds for nex-z trials in ATTR amyloidosis, and Intellia's financial runway is extended into 2028 with recent funding.
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics reported its first-quarter 2026 financial results and provided key business updates, highlighting positive Phase 3 HAELO data for lonvo-z in Hereditary Angioedema (HAE) and the initiation of its rolling BLA submission for potential U.S. launch in early 2027. The company also announced the resumption of patient screening for its Phase 3 trials of nex-z in ATTR amyloidosis and confirmed that existing cash resources, supplemented by a recent public offering, are expected to fund operations into 2028.
How Investors May Respond To Intellia Therapeutics (NTLA) Raising Capital And Advancing Its CRISPR HAE Therapy
Intellia Therapeutics recently completed a US$180 million stock offering and reported positive Phase 3 results for its CRISPR-based hereditary angioedema (HAE) therapy, lonvo-z, while initiating a rolling FDA biologics license application. These developments highlight lonvo-z's potential as a first-in-class, one-time treatment, shifting the investment focus towards commercialization timelines and regulatory progress. Investors should now weigh the dilution risk from the capital raise against the drug's strong clinical data and expedited regulatory path for a potentially transformative therapy in a rare disease.
Is Intellia Therapeutics (NTLA) Pricing Reflect Its Gene Editing Potential After Recent Price Surge
This article analyzes Intellia Therapeutics (NTLA) valuation after a recent price surge, using Discounted Cash Flow (DCF) and Price-to-Sales (P/S) ratios. While the DCF model suggests a significant undervaluation of 90.6% with an intrinsic value of $145.53 per share, the P/S ratio indicates the stock is overvalued compared to its fair ratio. The author emphasizes using "Narratives" to customize valuation based on individual investor outlooks for revenue and earnings.
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Intellia Therapeutics (NTLA) is projected to report increased earnings year-over-year but with lower revenues for the quarter ended March 2026. The company has a positive Earnings ESP of +6.14% and a Zacks Rank of #3, suggesting a strong likelihood of beating the consensus EPS estimate. Historically, Intellia Therapeutics has surpassed EPS estimates in the last four quarters, further supporting the anticipation of a positive surprise.
Cathie Wood’s ARK sells AMD stock, buys Tempus AI and Intellia
Cathie Wood's ARK Invest has made significant portfolio adjustments, selling 18,909 shares of Advanced Micro Devices (AMD) for over $6.7 million, continuing a trend of reducing its semiconductor exposure. Concurrently, ARK purchased 145,794 shares of Tempus AI Inc (TEM) for almost $7.9 million, showcasing its interest in the AI sector. The firm also increased its stake in Intellia Therapeutics Inc (NTLA) by buying 28,220 shares and further divested from Twist Bioscience Corp (TWST) by selling 61,351 shares.
Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying
Intellia Therapeutics (NTLA), a clinical-stage biotech firm specializing in CRISPR-based gene editing, has seen its stock drop nearly 95% from its 2021 peak due to safety concerns and lack of commercial revenue. Despite this, Cathie Wood has been steadily buying NTLA shares through her ARK ETFs, indicating long-term confidence in the high-risk, high-reward gene-editing sector. Recent positive Phase 3 results for Intellia's hereditary angioedema treatment and narrowing losses suggest a potential gradual recovery for the stock.
Three Intellia fireside chats will stream live through June 3
Intellia Therapeutics (Nasdaq: NTLA) announced its management will participate in three upcoming investor fireside chats in May and June 2026. These events include the Bank of America Securities Health Care Conference, RBC Capital Markets Global Healthcare Conference, and Jefferies Global Healthcare Conference. All sessions will be webcast live and replays will be available on Intellia's website for approximately 90 days.
Intellia Therapeutics Announces Investor Conference Participation on May 5, 2026
Intellia Therapeutics has announced its participation in upcoming investor conferences on May 5, 2026. The company aims to engage with the investment community to discuss and provide updates on its strategic initiatives. The announcement was made public at 11:30 AM GMT on Tuesday, May 5, 2026.
This Week’s CGT News: CRISPR Hits Phase 3 Milestone
Intellia Therapeutics has reported positive Phase 3 results for its CRISPR gene editing therapy lonvoguran ziclumeran (lonvo-z) for hereditary angioedema, marking a potential breakthrough as the first in vivo CRISPR-based therapy. Concurrently, Flagship Pioneering launched Serif Biomedicines to develop programmable DNA medicines, and Cabaletta Bio partnered with Cellares for large-scale CAR-T manufacturing for autoimmune diseases, highlighting significant advancements in the gene and cell therapy (CGT) landscape. Additionally, research from Rutgers University identified senescent immune cells as a factor in CAR-T therapy failure, and a natural compound was found to boost CAR-T potency, while eating was shown to enhance T-cell function with implications for immunotherapy timing.
Intellia Therapeutics to Participate in Upcoming Investor Conferences
Intellia Therapeutics, a biopharmaceutical company specializing in CRISPR gene editing, announced its participation in several upcoming investor conferences. Management will hold fireside chats at the Bank of America Securities Health Care Conference on May 12, 2026, the RBC Capital Markets Global Healthcare Conference on May 20, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026. Webcasts and replays of these events will be available on the company's website.
Is Intellia Therapeutics (NTLA) Pricing Reflect Its Gene Editing Potential After Recent Price Surge
This article analyzes whether Intellia Therapeutics (NTLA) is undervalued or overvalued, considering its recent price surge and gene editing potential. Using a Discounted Cash Flow (DCF) model and Price-to-Sales (P/S) ratio, the analysis suggests the stock is significantly undervalued by DCF but overvalued by P/S, prompting investors to consider various narratives for valuation. The company has seen substantial returns over the last year, despite still investing heavily in research.
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA
Levi & Korsinsky LLP has announced a class action securities lawsuit against Intellia Therapeutics, Inc. (NASDAQ: NTLA) for shareholders who suffered losses between July 30, 2024, and January 8, 2025. The lawsuit alleges that Intellia failed to disclose issues with its NTLA-3001 program, leading to a significant stock price drop following an announcement of its discontinuation and a 27% workforce reduction. Affected shareholders are encouraged to contact the firm to learn about their rights.
A Look At Intellia Therapeutics (NTLA) Valuation After Positive Phase 3 HAELO Results And FDA Filing Progress
Intellia Therapeutics (NTLA) is drawing attention after positive Phase 3 HAELO trial results for lonvoguran ziclumeran and starting its FDA biologics license application, leading to a recent stock price surge. Despite significant recent gains, the stock is considered 45.1% undervalued with a narrative fair value of $25.29 against its current price of $13.87, supported by improving financial discipline and a robust cash runway. However, a high price-to-sales ratio of 24.2x compared to the industry average of 11x suggests potential valuation risk if expectations are not met.
Intellia Therapeutics says its CRISPR-based treatment succeeds in pivotal trial
Intellia Therapeutics announced that its experimental CRISPR-based gene editing treatment, NTLA-2001, met its primary endpoint in a pivotal Phase 3 trial. The therapy significantly reduced serum levels of transthyretin (TTR) compared to placebo in patients with transthyretin amyloidosis with cardiomyopathy. This positive outcome marks a significant advancement for Intellia and the potential of CRISPR technology in treating genetic diseases.
Intellia Therapeutics (Nasdaq:NTLA) - Stock Analysis
This report provides an in-depth stock analysis of Intellia Therapeutics (NTLA), a clinical-stage genome editing company. It covers valuation, future growth prospects, past performance, financial health, management, and ownership, estimating the stock to be 47.4% undervalued compared to analyst consensus targets. The article also highlights recent news, clinical trial updates, and analyst sentiments, particularly regarding the FDA's decision to lift clinical holds on the MAGNITUDE programs.
Intellia Initiates Rolling BLA Submission For In Vivo CRISPR Therapy In Hereditary Angioedema
Intellia Therapeutics has begun a rolling submission of a Biologics License Application (BLA) to the FDA for lonvoguran ziclumeran (lonvo-z), its investigational in vivo CRISPR-based gene editing therapy for hereditary angioedema (HAE). This submission follows positive Phase 3 clinical trial results, where most patients achieved freedom from HAE attacks after a single dose. If approved, lonvo-z would be the first in vivo CRISPR-based gene editing therapy on the market, with a potential launch in the first half of 2027.
43 new Intellia employees get stock awards worth 208,850 shares
Intellia Therapeutics announced inducement awards of 208,850 restricted stock units (RSUs) to 43 new employees. These awards, vesting annually over three years, are part of the company's 2024 Inducement Plan and were approved under Nasdaq Listing Rule 5635(c)(4). The grants serve as a material inducement for new hires and were issued outside of Intellia's stockholder-approved equity incentive plans.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. announced that on May 1, 2026, it awarded inducement grants to 43 new employees. These grants consisted of restricted stock units (RSUs) totaling 208,850 shares of common stock, vesting annually over three years. The awards were approved by Intellia's compensation committee as a material inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics Prices Public Equity Offering to Fund Pipeline
Intellia Therapeutics successfully raised approximately $194.6 million through a public equity offering to fund its pipeline and operations into 2028. The company plans to use these proceeds for clinical development, commercial launch preparation, new candidate research, potential acquisitions, and general corporate purposes. This financial move strengthens Intellia's balance sheet ahead of potential regulatory approval for lonvoguran ziclumeran in 2027.
Intellia Files BLA After Lonvo-z Meets Phase 3 Endpoints
Intellia Therapeutics has initiated a rolling Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z) to treat hereditary angioedema (HAE) following positive Phase 3 HAELO trial results. Lonvo-z, an in vivo CRISPR-Cas gene editing therapy, significantly reduced HAE attacks and met all secondary endpoints, positioning it to be the first approved therapy of its kind. The company anticipates completing the filing in late 2026 and commercial launch in early 2027, pending FDA approval.
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
Intellia Therapeutics, Inc. announced the pricing of an underwritten public offering of 16,744,187 shares of its common stock at $10.75 per share, expecting to raise approximately $180 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase an additional 2,511,628 shares. Jefferies, Goldman Sachs & Co. LLC, and Citigroup are acting as joint book-running managers for the offering.
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
Intellia Therapeutics, Inc. announced the pricing of an underwritten public offering of 16,744,187 shares of its common stock at $10.75 per share, expecting to raise approximately $180 million in gross proceeds. The company also granted underwriters a 30-day option to purchase up to an additional 2,511,628 shares. Jefferies, Goldman Sachs & Co. LLC, and Citigroup are acting as joint book-running managers for the offering.
Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder
Intellia Therapeutics' experimental gene-editing medicine, lonvo-z, successfully met its primary objective in a Phase 3 trial for hereditary angioedema (HAE), reducing swelling attacks by 87% compared to placebo. This positions Intellia to seek approval for what would be the first in vivo gene-editing treatment for HAE, despite ongoing investor skepticism about its commercial potential in a market with existing effective therapies. The therapy showed a "favorable" safety profile, and the company plans a U.S. approval submission, aiming for a launch in the first half of 2027.
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
Intellia Therapeutics has begun a rolling submission of its Biologics License Application (BLA) to the FDA for lonvoguran ziclumeran (lonvo-z) as a one-time treatment for hereditary angioedema (HAE). The company anticipates completing the BLA by the second half of 2026 and aims for a commercial launch in the first half of 2027, if approved. This CRISPR-based gene editing therapy has shown promising results in the Phase 3 HAELO trial, with most patients achieving freedom from HAE attacks and the need for ongoing therapy after a single dose.
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
Intellia Therapeutics, Inc. (Nasdaq: NTLA) has initiated an underwritten public offering to sell $150 million worth of its common stock. The company also plans to grant underwriters a 30-day option to purchase an additional 15% of the shares. Jefferies, Goldman Sachs & Co. LLC, and Citigroup are serving as joint book-running managers for the offering, which is subject to market conditions.
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late
Intellia Therapeutics (NTLA) shares surged pre-market following positive late-stage trial data for its gene-editing therapy, lonvoguran ziclumeran (lonvo-z), for hereditary angioedema (HAE). The therapy met primary and secondary endpoints, with 62% of patients free of HAE attacks, compared to 11% on placebo. Intellia has initiated a rolling Biologics License Application submission to the FDA and aims for a U.S. launch in the first half of 2027.
Intellia Therapeutics Initiates Rolling Submission of
Intellia Therapeutics has begun a rolling submission of a biologics license application (BLA) to the FDA for lonvoguran ziclumeran (lonvo-z), a one-time gene-editing treatment for hereditary angioedema (HAE). This submission follows positive Phase 3 HAELO trial results, which showed lonvo-z freed most patients from HAE attacks and ongoing therapy. The company expects to complete the BLA by the second half of 2026 and, if approved, plans a commercial launch in the first half of 2027.
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Intellia Therapeutics announced positive topline results from its global Phase 3 HAELO clinical trial for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE), marking the first Phase 3 data for an in vivo gene editing therapy. The trial met its primary and all key secondary endpoints, demonstrating that a single dose of lonvo-z significantly reduced HAE attacks and freed most patients from ongoing therapy for six months. Intellia has initiated a rolling Biologics License Application (BLA) submission with the U.S. FDA, anticipating a potential U.S. launch in the first half of 2027 if approved.
Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout
Intellia Therapeutics stock surged 19.3% after hours ahead of the upcoming release of top-line Phase 3 data for its in vivo CRISPR gene-editing therapy, lonvoguran ziclumeran, for hereditary angioedema. The company expects to announce results from its HAELO trial on Monday, April 27, 2026, which could lead to a U.S. biologics license application later this year. Investors will be closely watching for attack-rate reduction and safety data, especially given past clinical hold issues with another program.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of "Hold" by Brokerages
Intellia Therapeutics (NASDAQ:NTLA) has received a "Hold" consensus rating from twenty brokerages, with an average one-year price target of $19.52. Despite this, some analysts have recently upgraded the stock or increased price targets, reflecting rising enthusiasm. The company recently beat quarterly revenue and EPS estimates but remains unprofitable.
Intellia Readies First Phase 3 In Vivo CRISPR Test For HAE Thesis
Intellia Therapeutics is preparing to announce topline results from the first Phase 3 trial of an in vivo CRISPR gene editing candidate for hereditary angioedema (HAE). This will be the first-ever Phase 3 data release for an in vivo CRISPR therapy and is highly anticipated by the biotech industry. The results will be crucial for Intellia's future and could significantly influence the broader gene editing drug development landscape.
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
Intellia Therapeutics, Inc. announced it will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026. This will be the world's first Phase 3 readout for an in vivo CRISPR gene editing candidate. The company will also host a webcast at 8:00 a.m. ET on that day to discuss the data.
